Lupin Limited

NSE: LUPIN · Pharmaceuticals · sector

₹1,959.90NSE close 2026-10-26

Key numbers

Market cap₹89,616 cr

Price₹1,959.90

52w high / low₹2,530 / ₹1,900

P/E16.2xSector median 27.9x

P/B4.0xSector median 2.9x

Book value₹490.9

Dividend yield0.61%Sector median 0.48%

ROE27.9%Sector median 11.7%

ROCE27.9%Sector median 12.3%

OPM30.0%Sector median 14.0%

Debt / equity0.26xSector median 0.16x

EV/EBITDA9.6xSector median 18.6x

Interest cover17.5x

Current ratio1.90x

Sales growth 3y+18.9%Sector median +9.6%

Profit growth 3y+131.5%Sector median +13.3%

PEG0.12x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹9,230 cr vs borrowings ₹5,910 cr (FY26): cash is higher (net cash).
Operating profit covered interest 17.5x in the last 12 months.
No promoter shares are pledged.
Operating cash flow was below net profit in 1 of the last 5 years (FY25).
Revenue was higher than a year earlier in 4 of the last 4 quarters.
Other income was 9% of net profit in the last 12 months.
Dividend paid in 5 of the last 5 financial years.
Price ₹1,959.90 on 2026-10-26: -22.5% from the 52-week high, +3.2% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹2,493.00 · low ₹1,864.50

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	5,673	5,768	5,667	6,268	7,048	7,168	7,475	8,277
EBITDA	1,340	1,356	1,321	1,727	2,341	1,835	2,354	2,450
OPM %	23.6%	23.5%	23.3%	27.6%	33.2%	25.6%	31.5%	29.6%
Other income	42	54	57	79	90	115	141	130
Net profit	853	855	773	1,219	1,478	1,176	1,460	1,415
EPS (₹)	18.70	18.75	16.93	26.70	32.36	25.74	31.96	30.95
Revenue YoY					+24.2%	+24.3%	+31.9%	+32.0%
Profit YoY					+73.3%	+37.5%	+89.0%	+16.1%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	16,405	16,642	20,011	22,708	27,958	29,967
EBITDA	287	1,798	3,811	5,283	8,258	8,980
Net profit	-1,528	430	1,914	3,282	5,333	5,529
EPS (₹)	-33.65	9.46	42.05	71.95	116.75	121.01
Revenue growth		+1.4%	+20.2%	+13.5%	+23.1%	+28.2%
Profit growth		–	+345.1%	+71.4%	+62.5%	+49.5%
Dividend / share (₹)	6.50	4.00	4.00	8.00	12.00

Compounded growth	3 years	5 years	Last 12 months
Sales	+18.9%	+13.0%	+28.2%
Net profit	+131.5%	+34.4%	+49.5%
EPS	+131.1%	+33.9%	–
Share price	–	-4.5% (2y)	+1.1%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	12,464	14,290	17,204	22,448
Borrowings	–	4,244	2,670	5,077	5,910
Cash & equivalents	–	1,733	2,049	4,201	9,230
Total assets	–	22,956	23,997	29,205	38,365
Fixed assets	–	4,645	4,899	5,148	5,449
Capital work in progress	–	895	596	355	695
Investments	–	47	201	60	64
Receivables	–	4,481	4,692	5,497	6,604
Inventory	–	4,492	4,954	5,476	6,083
Payables	–	2,532	2,958	2,958	4,173

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	1,082	1,934	3,490	430	7,546
Cash from investing	577	-1,324	-1,554	-1,602	-4,076
Cash from financing	-1,572	-337	-2,184	1,732	-846
Capex	905	1,500	929	1,682	2,055
Free cash flow	177	434	2,562	-1,252	5,491

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	3.5%	13.4%	19.1%	23.8%
ROCE %	–	5.9%	16.1%	19.3%	25.8%
Debtor days	–	98	86	88	86
Inventory days	–	242	272	292	303
Payable days	–	136	163	158	208
Cash conversion cycle (days)	–	204	195	222	181
Working capital days	–	70	90	126	149

Shareholding

Holder	% (2026-09-30)
Promoters	46.84%
FIIs	23.28%
DIIs	23.78%
of which Mutual funds	14.58%
of which Insurance	6.38%
Government	0.00%
Public (non-institutions)	6.09%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	46.95%	46.92%	46.90%	46.90%	46.89%	46.86%	46.85%	46.84%

Promoter group	%
Lupin Investments Private Limited	45.31%
Manju D Gupta	0.85%
Nilesh Gupta	0.20%
Anuja Gupta	0.16%
D B Gupta HUF (Nilesh Deshbandhu Gupta, Karta of HUF)	0.14%
Vinita Gupta	0.07%
Richa Gupta	0.05%
Kavita Gupta	0.04%
Veda Nilesh Gupta	0.02%
Neel Deshbandhu Gupta	0.01%
Shefali Nath Gupta	0.00%
Manju D Gupta (As a Trustee of Gupta Family Trust)	0.00%

Public holders above 1%	%
HDFC Mutual Fund-HDFC Arbitrage Fund	4.68%
LICI New Pension Plus Growth Fund	3.90%
NPS Trust- A/C ICICI Pension Fund Scheme E - Tier I	2.63%
Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund	2.33%
Mirae Asset BSE LARGEMID (60:40) Stable Dividend 50 ETF	1.88%
Sbi Arbitrage Fund	1.13%

2,97,301 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
LUPIN	₹89,616 cr	16.2x	4.0x	27.9%	27.9%	30.0%	+18.9%	0.61%

All 185 companies in Pharmaceuticals →

Business segments (FY26)

Segment	Revenue	Share	EBIT	Margin
Pharmaceuticals	₹27,812 cr	99.5%	₹7,050 cr	25.3%
Others	₹147 cr	0.5%	₹-178 cr	-120.6%
Less: Inter segment Assets	₹0 cr	–	₹0 cr	–
Less: Inter segment Liabilities	₹0 cr	–	₹0 cr	–

Dividends & corporate actions

Ex-date	Action	Detail
2026-07-17	Dividend	Dividend - Rs 18 Per Share
2025-07-25	Dividend	Dividend - Rs 12 Per Share
2024-07-16	Dividend	Dividend - Rs 8 Per Share
2023-07-14	Dividend	Dividend - Rs 4 Per Share
2022-07-14	Dividend	Dividend - Rs 4 Per Share
2021-07-27	Dividend	Dividend - Rs 6.50 Per Share
2020-08-03	Dividend	Annual General Meeting/Dividend - Rs 6 Per Share
2019-07-29	Dividend	Annual General Meeting/Dividend - Rs 5 Per Share
2018-07-30	Dividend	Annual General Meeting/Dividend Rs 5/- Per Share
2017-07-24	Dividend	Annual General Meeting/Dividend - Rs 7.50 Per Share
2016-07-25	Dividend	Annual General Meeting/ Dividend -Rs 7.50/- Per Share
2015-07-14	Dividend	Annual General Meeting/ Dividend - Rs 7.50/- Per Share
2014-07-21	Dividend	Annual General Meeting / Final Dividend - Rs 3/- Per Share
2014-02-13	Dividend	Interim Dividend - Rs 3/- Per Share
2013-07-29	Dividend	Annual General Meeting / Dividend - Rs 4/- Per Share
2012-07-13	Dividend	Annual General Meeting And Dividend Rs.3.20 Per Share
2011-07-18	Dividend	Annual General Meeting And Dividend Rs.3/- Per Share
2010-08-27	Split	Face Value Split From Rs.10/- To Rs.2/-
2010-07-19	Dividend	Annual General Meeting And Dividend Rs.13.50 Per Share
2009-07-20	Other	Agm/Div-Rs.12.50 Pr Share

Documents

Links go to the original files on the exchange website.

About the company

Manufacture of Pharmaceuticals: Manufacturing and sales of Pharmaceuticals


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	LUPIN
BSE code	500257
ISIN	INE326A01037
Face value	₹2.0
Incorporated	1983-03-01
Website	www.lupin.com
Plants (India / abroad)	12 / 3

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.